RMS

1,658.5

+1.87%↑

BMW

77.72

+4.66%↑

VOW

87.85

+2.57%↑

VOW3

86.08

+2.4%↑

KER

248.65

+5.43%↑

RMS

1,658.5

+1.87%↑

BMW

77.72

+4.66%↑

VOW

87.85

+2.57%↑

VOW3

86.08

+2.4%↑

KER

248.65

+5.43%↑

RMS

1,658.5

+1.87%↑

BMW

77.72

+4.66%↑

VOW

87.85

+2.57%↑

VOW3

86.08

+2.4%↑

KER

248.65

+5.43%↑

RMS

1,658.5

+1.87%↑

BMW

77.72

+4.66%↑

VOW

87.85

+2.57%↑

VOW3

86.08

+2.4%↑

KER

248.65

+5.43%↑

RMS

1,658.5

+1.87%↑

BMW

77.72

+4.66%↑

VOW

87.85

+2.57%↑

VOW3

86.08

+2.4%↑

KER

248.65

+5.43%↑

Search

D'ieteren SA-NV

Închisă

SectorConsumator ciclic

161 0.12

Rezumat

Modificarea prețului

24h

Curent

Minim

153.5

Maxim

163.8

Indicatori cheie

By Trading Economics

Venit

-68M

176M

Vânzări

-71M

4B

P/E

Medie Sector

21.954

33.36

Randament dividend

1.16

Marjă de profit

4.413

Angajați

12,366

EBITDA

-21M

304M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+34.21% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

1.16%

3.17%

Statistici piață

By TradingEconomics

Capitalizare de piață

-234M

9.2B

Deschiderea anterioară

160.88

Închiderea anterioară

161

Sentimentul știrilor

By Acuity

50%

50%

140 / 338 Clasament în Consumer cyclical

D'ieteren SA-NV Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

23 mar. 2026, 23:47 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

23 mar. 2026, 22:55 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

23 mar. 2026, 21:51 UTC

Achiziții, Fuziuni, Preluări

Italy's Postal Service Makes $12.50 Billion Bid for Telecom Italia -- 3rd Update

23 mar. 2026, 23:59 UTC

Market Talk

Global Equities Roundup: Market Talk

23 mar. 2026, 23:59 UTC

Market Talk

Woodside, Santos Earnings Power Up on Surging LNG Prices -- Market Talk

23 mar. 2026, 23:50 UTC

Market Talk

Nikkei May Rise on Hopes for U.S. Talks With Iran -- Market Talk

23 mar. 2026, 23:37 UTC

Market Talk

Gold Rises, Boosted by Fall in Dollar, U.S. Treasury Yields -- Market Talk

23 mar. 2026, 22:42 UTC

Market Talk
Evenimente importante

Global Equities Roundup: Market Talk

23 mar. 2026, 22:42 UTC

Market Talk
Evenimente importante

Bell Potter Names Miners Less Exposed to Fuel Price, Supply Risks -- Market Talk

23 mar. 2026, 22:40 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

23 mar. 2026, 22:23 UTC

Market Talk

Apollo Debt Solutions Shrugs Off Private-Credit Fears -- Market Talk

23 mar. 2026, 22:22 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

23 mar. 2026, 22:21 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales

23 mar. 2026, 22:21 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China

23 mar. 2026, 22:20 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD

23 mar. 2026, 22:20 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD

23 mar. 2026, 22:19 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders

23 mar. 2026, 22:19 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets

23 mar. 2026, 22:18 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences to Buy Ouro Medicines for About $1.68B Upfront, Up to $500M in Contingent Milestone Payments >GILD

23 mar. 2026, 22:15 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases >GILD

23 mar. 2026, 22:08 UTC

Market Talk

Ebos Needs to Reset Its Gearing Targets -- Market Talk

23 mar. 2026, 21:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

23 mar. 2026, 21:42 UTC

Market Talk

RBNZ's Breman Strikes Reassuring Tone On Rates -- Market Talk

23 mar. 2026, 21:32 UTC

Câștiguri

WuXi XDC Cayman: Results Aided by Strong Growth in Contract Research, Development and Manufacturing Organisation Business>2268.HK

23 mar. 2026, 21:32 UTC

Câștiguri

WuXi XDC Cayman 2025 Net CNY1.56B Vs. Net CNY917.16M >2268.HK

23 mar. 2026, 21:32 UTC

Câștiguri

WuXi XDC Cayman 2025 Rev CNY5.94B Vs. CNY4.05B >2268.HK

23 mar. 2026, 21:10 UTC

Evenimente importante

Oil Is Back Under $100. Trump Says Iran Has Agreed to No Nuclear Weapons. -- Barrons.com

23 mar. 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

23 mar. 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

23 mar. 2026, 20:50 UTC

Market Talk
Câștiguri
Evenimente importante

Basic Materials Roundup: Market Talk

Comparație

Modificare preț

D'ieteren SA-NV Așteptări

Obiectiv de preț

By TipRanks

34.21% sus

Prognoză pe 12 luni

Medie 215 EUR  34.21%

Maxim 215 EUR

Minim 215 EUR

În baza a 1 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruD'ieteren SA-NV - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

1 ratings

1

Cumpărare

0

Păstrare

0

Vânzare

Sentiment

By Acuity

140 / 338 Clasament în Consumator ciclic

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Medie

Date financiare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre D'ieteren SA-NV

D'Ieteren Group SA operates as an investment company in Belgium, France, rest of Europe, the Middle East, Africa, America, the Asia-Pacific, and internationally. The company operates through D'Ieteren Automotive, Belron, Moleskine, TVH, and PHE segments. It distributes Volkswagen, Audi, SEAT, "KODA, CUPRA, Bentley, Lamborghini, Bugatti, Rimac, Porsche, and Microlino brand vehicles, as well as related spare parts and accessories; sells used vehicles; and offers maintenance, financing, and leasing services. The company also provides vehicle glass repair, replacement, and recalibration services under the Autoglass, Carglass, Lebeau Vitres d'autos, Speedy Glass, Safelite AutoGlass, O'Brien, and Smith&Smith brand names; and manages vehicle glass and other insurance claims on behalf of insurance customers. In addition, it offers notebooks, writing tools, planners, diaries, bags, and reading accessories, as well as smart writing system and mobile apps. Further, the company distributes aftermarket parts for material handling, construction, agricultural, and industrial equipment. Additionally, it manages real estate assets, including offices, workshops, concessions, logistics centers, residential units, car parks, and landbanks; reconverts and redevelops sites; and offers real estate advisory services. D'Ieteren Group SA was founded in 1805 and is headquartered in Brussels, Belgium.
help-icon Live chat